Scarica l'app Stockscreener
14.58
6.54%
-1.02
Dopo l'orario di chiusura:
14.71
0.13
+0.89%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Kalvista Pharmaceuticals Inc Borsa (KALV) Ultime notizie
What analysts say about KalVista Pharmaceuticals Inc. stock outlookPhenomenal capital gains - jammulinksnews.com
New medicines recommended for approval by EMA’s CHMP - The Pharma Letter
What analysts say about KalVista Pharmaceuticals Inc. stockFree Daily Trading Room Entry - Autocar Professional
KalVista receives CHMP opinion recommending sebetralstat marketing authorization - TipRanks
KalVista, Biogen, Ionis get EU positive opinions for key drugs (KALV:NASDAQ) - Seeking Alpha
European regulator recommends approval of first oral HAE treatment - Investing.com India
KalVista Pharma Announces Positive CHMP Opinion For Sebetralstat - Nasdaq
KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks - Business Wire
What drives KalVista Pharmaceuticals Inc. stock priceFree Daily Trading Room Entry - PrintWeekIndia
US FDA Cancer Reviewers Heading For The Exits, Potentially Impacting Review Timelines - insights.citeline.com
KalVista Pharmaceuticals Inc. Stock Analysis and ForecastRobust investment performance - jammulinksnews.com
Is KalVista Pharmaceuticals Inc. a good long term investmentRapid return acceleration - jammulinksnews.com
Friedreich's Ataxia Market Is Expanding Due To Advancing - openPR.com
Kalvista Pharmaceuticals stock maintains Market Outperform rating at JMP By Investing.com - Investing.com South Africa
Kalvista Pharmaceuticals stock maintains Market Outperform rating at JMP - Investing.com India
(KALV) Proactive Strategies - news.stocktradersdaily.com
JMP reiterates Market Outperform rating on Kalvista stock after UK approval By Investing.com - Investing.com South Africa
JMP reiterates Market Outperform rating on Kalvista stock after UK approval - Investing.com Nigeria
KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema - BioSpace
KalVista Pharmaceuticals Gets UK Approval for Hereditary Angioedema Treatment - MarketScreener
KalVista Pharmaceuticals announces UK MHRA approval of Ekterly (sebetralstat) - MarketScreener
KalVista gets UK nod for Ekterly (KALV:NASDAQ) - Seeking Alpha
UK approves first oral treatment for hereditary angioedema attacks By Investing.com - Investing.com Canada
(sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema - Business Wire
MHRA approves Ekterly to treat HAE - The Pharma Letter
KalVista Pharmaceuticals Wins UK Approval for Hereditary Angioedema Treatment - MarketScreener
Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Have Insiders Sold KalVista Pharmaceuticals Shares Recently? - simplywall.st
The week in pharma: action, reaction and insight – week to July 11 - The Pharma Letter
Kalvista stock maintains Buy rating at H.C. Wainwright on favorable Ekterly label - Investing.com Nigeria
KalVista:HC Wainwright Raises PT to $27, Maintains Buy Rating - AInvest
Kalvista Pharma chief development officer sells $474k in shares By Investing.com - Investing.com Canada
KalVista Pharmaceuticals: EKTERLY Launch and Financial Update - TipRanks
Kalvista Pharma chief development officer sells $474k in shares - Investing.com Australia
Kalvista Pharma CEO Palleiko sells $517k in shares By Investing.com - Investing.com South Africa
Kalvista Pharma CEO Palleiko sells $517k in shares - Investing.com Australia
0.97%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):